Tournament co-hosts India will be out to defend their Twenty20 World Cup title. The 10th edition of the 20-overs global showpiece event will run from February 7 to March 8.
Tournament co-hosts India will be out to defend their Twenty20 World Cup title in familiar home conditions next month.
Sun Pharmaceutical's three-year battle to take control of Israel's Taro Pharmaceutical is far from over. The Indian company will now go all out to acquire shares from promoter Barrie Levitt and family, who hold over 40 per cent voting rights in the company.
Sun Pharmaceutical may face legal battles in New York courts in its attempt to take over the Israeli drug major Taro Pharmaceuticals, unless its chairman Barrie Levitt and family give up in a few weeks. This is despite the green signal given by an Israel court to proceed with the tender offer.
Sun Pharma rejected Taro's demand, stating that it had not disclosed audited results for the past three years as well as the restated accounts. Sun's offer was a maximum of $9.50 per share, with two options. Discussions failed and both parties asked the court to give a verdict. However, the court directed both parties to re-negotiate through a mediator.
Sun Pharmaceutical Industries and Israel-based Taro Pharmaceutical have started fresh rounds of negotiations to settle their differences over a takeover by the Indian company out of court.
Seeking the support of its shareholders, Taro chairman and managing director Barrie Levitt said, "We believe that Sun may now attempt to seize the control of your company by waging a proxy fight to gain control of the Taro board."
Sun Pharma's share price jumped 5.62 per cent on the Bombay Stock Exchange after it gained a new ally in its legal battle to acquire Israel's Taro Pharmaceuticals with minority investor Templeton Asset Management switching sides to support Sun's bid.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances